Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Rectal Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Lung Neoplasms 2Esophageal Neoplasms 2Breast Neoplasms 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Kidney Neoplasms 1Head and Neck Neoplasms 1Esthesioneuroblastoma, Olfactory 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms, Male 1Adenocarcinoma Of Esophagus 1

Interventions

Rituximab 55Cyclophosphamide 41Lenalidomide 25Vincristine 23Doxorubicin 22Prednisone 21Etoposide 16ibrutinib 12Gemcitabine 12fludarabine phosphate 10fludarabine 10Peripheral Blood Stem Cell Transplantation 10Carboplatin 10Bendamustine Hydrochloride 10Ifosfamide 9Filgrastim 8polatuzumab vedotin 7obinutuzumab 7Oxaliplatin 7Mycophenolic Acid 7Methotrexate 6Cyclosporine 6venetoclax 5tafasitamab 5Vorinostat 5Radiotherapy 5R-CHOP protocol 5Prednisolone 5Melphalan 5Granulocyte Colony-Stimulating Factor 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, Large B-Cell, Diffuse × oblimersen × Clear all
NCT00086944 2013-01-24

Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Completed
25 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡